Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Tony Sedgwick, Thomas Christely

Premium

Silence Therapeutics has appointed chief business officer Tony Sedgwick as its new CEO following the resignation of Thomas Christely.

Sedgwick joined Silence last September. Before that, he was CEO of Novacta, Daniolabs, and Cambridge Biotechnology.

Christely was previously CEO of Atugen, which was later acquired by Silence. He had served as Silence's COO until the departure of former CEO Philip Haworth last year. Silence said that Christely has also resigned his board seat.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.